Breast Cancer: S0012 (Hematology Oncology Associates)

S0012 Comparative Randomized Study of Standard Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide followed by Paclitaxel as Neoadjuvant Therapy for Inflammatory and Locally Advanced Breast Cancer.

Objective

The main purpose of this study is to compare two different treatments (or "regimens") for breast cancer prior to surgery to see if one works better against breast cancer than the other.

One treatment includes the drugs doxorubicin and cyclophosphamide given through a needle in a vein on Day 1 every 21 days, five times followed by paclitaxel treatment once every week for 12 weeks. The other treatment includes the same two drugs but the doxorubicin is given through a needle in the vein once a week for 15 weeks and the cyclophosphamide is given by pill every day for 15 weeks followed by paclitaxel treatment once every week for 12 weeks. The two drugs filgrastim and trimethoprim sulfa are also given with doxorubicin/ cyclophosphamide part of the second treatment regimen. The other purpose of this study is to compare the type and severity of the side effects of each of these two treatment regimens.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Sponsor(s)
SWOG
Contact
Katy D'Aprile, RN, BSN at 563-355-7733

Location

  • Hematology Oncology Associates of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email